-
公开(公告)号：US20250020661A1
公开(公告)日：2025-01-16
申请号：US18902725
申请日：2024-09-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Thomas Dieterle , Olav Lapaire
IPC: G01N33/68
Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
-
公开(公告)号：US10684291B2
公开(公告)日：2020-06-16
申请号：US15220555
申请日：2016-07-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
-
公开(公告)号：US20190277861A1
公开(公告)日：2019-09-12
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US11047866B2
公开(公告)日：2021-06-29
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
-
5.发明申请公开(公告)号：US20200378981A1
公开(公告)日：2020-12-03
申请号：US16998444
申请日：2020-08-20
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Thomas Dieterle , Olav Lapaire
IPC: G01N33/68
Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
-
Patent Agency Ranking
公开(公告)号：US10234464B2
公开(公告)日：2019-03-19
申请号：US15054255
申请日：2016-02-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
-
公开(公告)号：US20170010283A1
公开(公告)日：2017-01-12
申请号：US15274533
申请日：2016-09-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2800/325
Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
Abstract translation: 本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。 该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选地至少一个其他标记物的水平，并将该水平与参考水平进行比较。 进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。 本发明还包括适用于实施本发明方法的试剂盒和装置。
-
公开(公告)号：US12117454B2
公开(公告)日：2024-10-15
申请号：US16868644
申请日：2020-05-07
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
CPC classification number: G01N33/6893 , G01N33/62 , G01N33/66 , G01N33/6869 , G01N33/6887 , G01N33/70 , G01N33/723 , G01N33/84 , G01N2333/4737 , G01N2333/5412 , G01N2333/58 , G01N2333/78 , G01N2333/805 , G01N2800/325 , G01N2800/347 , G01N2800/52
Abstract: Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.
-
9.发明申请公开(公告)号：US20200271670A1
公开(公告)日：2020-08-27
申请号：US16868644
申请日：2020-05-07
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
-
公开(公告)号：US20190154706A1
公开(公告)日：2019-05-23
申请号：US16257770
申请日：2019-01-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.025 seconds)
